<DOC>
	<DOCNO>NCT01755871</DOCNO>
	<brief_summary>The purpose study explore immunomodulatory immunosuppressive mechanism action fingolimod patient Relapsing remit multiple Sclerosis collect data biomarkers initiation fingolimod treatment .</brief_summary>
	<brief_title>Long-term Effect Fingolimod Circulating Immunocompetent Mononuclear Cells Patients With Multiple Sclerosis</brief_title>
	<detailed_description>After treatment fingolimod blood patient collect different time point examine change T cell , B cell biomarkers .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>1 . Written informed consent patient capable give withhold full informed consent must obtain assessment perform trial . 2 . Male female subject age 1865 year . 3 . Subjects relapse remit form MS define 2010 revise McDonald criterion ( see Appendix ) . 4 . Patients high disease activity despite treatment disease modify therapy ( ≥ 1 relapse previous year , ≥ 9 hyperintense T2 lesion ≥1 Gdenhancing lesion `` nonresponding '' could define unchanged increase relapse rate ongoing severe relapse compare previous year ) patient rapidly evolve severe RRMS ( e.g . ≥ 2 relapse disease progression one year ≥ 1 Gdenhancing lesion significant increase T2 lesion compare recent MRI ) . 5 . Patients Expanded Disability Status Scale ( EDSS ) score 06.5 ( see Appendix ) . 6 . Sufficient ability read , write , communicate understand 1 . Patients manifestation MS relapse remit MS. 2 . Patients history chronic disease immune system MS , require systemic immunosuppressive treatment , know immunodeficiency syndrome . 3 . History presence malignancy ( localize basal cell carcinoma skin carcinoma situ cervix ) last 5 year 4 . Diabetic patient moderate severe nonproliferative diabetic retinopathy proliferative diabetic retinopathy uncontrolled diabetic patient HbA1c &gt; 7 % . 5 . Diagnosis macular edema Baseline Visit ( patient history macular edema allow enter study provide macular edema ophthalmic baseline visit ) . 6 . Patients active systemic bacterial , viral fungal infection , know AIDS , Hepatitis B , Hepatitis C infection positive HIV antibody , Hepatitis B surface antigen Hepatitis C antibody test . 7 . Negative varicellazoster virus IgG antibodies Baseline . 8 . Have receive live live attenuate vaccine ( include varicellazoster virus measles ) within 1 month prior baseline . 9 . Patients receive total lymphoid irradiation bone marrow transplantation . 10 . Patients expect treated disease modify drug ( DMD ) study ( i.e . IFNβ , glatiramer acetate ) ; however washout need DMDs prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>